SHAREHOLDER ALERT: Investigation of TG Therapeutics, Inc. (TGTX) Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - January 27, 2022) - Holzer & Holzer, LLC is investigating whether TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) complied with federal securities laws. On January 27, 2022, Seeking Alpha published an article entitled "TG Therapeutics drops 30% after CEO discloses partial clinical hold on studies." The article stated that the CEO of TG Therapeutics, Michael Weiss, disclosed during a financial conference that no new patients can be enrolled in some chronic lymphocytic leukemia and non-Hodgkin's lymphoma trials. Following the report, the Company's stock dropped.

If you purchased TG Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111880